< formatted article >

Science Corp: Pioneering the Future of Brain-Machine Integration

A Tiny Sensor with Giant Ambitions

Science Corp isn’t chasing thrills—it’s chasing breakthroughs. The company is set to place a 520-electrode sensor, no larger than a pea, on the surface of a human brain during an already scheduled operation. This isn’t speculative science; it’s a strategic trial to test the device’s safety and precision.

Scheduled for 2027, the first trial will be led by Murat Günel, chair of neurosurgery at Yale. Instead of recruiting healthy volunteers, Science Corp is targeting patients who need brain surgery anyway—stroke victims, for example. This "opportunistic" approach minimizes additional risk for those already facing major procedures.

Beyond Recording: The Biohybrid Future

What sets Science Corp apart isn’t just the sensor—it’s the vision for what comes next.

The company is betting on a future where lab-grown neurons, engineered to respond to light, could bridge the gap between biology and electronics. Imagine a chip that doesn’t just record signals but grows with the brain, forming a natural, dynamic connection.

For now, the first sensor is hardware-only—a test to ensure safe, reliable data capture. Success here would be just the beginning. The real challenge? Integrating living neurons into the system, creating a seamless fusion of mind and machine.

The Brain-Computer Race: Who’s Leading?

Science Corp isn’t alone in the race. The field is heating up:

• Neuralink (founded by ex-Science Corp employees) has already implanted its device in over 20 people, focusing on dense electrodes and automation.
• Paradromics is pushing for raw speed, prioritizing lightning-fast data transfer.
• Synchron takes a less invasive route, threading its device through blood vessels to minimize surgical risk.

Each player is placing a different bet. Science Corp? It’s wagering that biology—specifically, lab-grown neurons—will dominate the long game.

---

A Rare Win: Restoring Vision with PRIMA

While brain interfaces grab headlines, Science Corp is already making waves in another domain.

Its retinal implant, PRIMA, is smaller than a grain of salt and sits beneath the retina, restoring vision in patients with severe eye damage.

Results from a 12-month trial were striking:

• 38 patients showed significant improvement.
• Most could read letters and words—a rarity in a field where treatments usually only slow degeneration.

Already approved in some regions, PRIMA could reach European markets by mid-2026.

---

The Big Bet: $1.5 Billion and a Race to the Future

Science Corp’s latest funding round—a $230 million boost in 2026—values the company at $1.5 billion. With 150 employees, it’s growing fast, but still a small player in a crowded field.

The real test? Whether its biohybrid vision—neurons and all—can outperform the competition.

For now, the first sensor placement is just the beginning. It’s a high-stakes gamble on a future where brains and machines work as one.